Valuation: Krystal Biotech, Inc.

Market Cap 9.51B 8.54B 7.89B 7.15B 13.35B 906B 13.51B 94.35B 37.58B 474B 35.7B 34.95B 1,505B P/E 2026 *
44.2x
P/E 2027 * 35.6x
Enterprise Value 8.9B 7.99B 7.39B 6.69B 12.5B 848B 12.65B 88.3B 35.17B 444B 33.41B 32.7B 1,409B EV / Sales 2026 *
17.9x
EV / Sales 2027 * 13.4x
Free-Float
89.34%
Yield 2026 *
-
Yield 2027 * -
1 day+0.21%
1 week+0.66%
Current month-3.10%
1 month-3.82%
3 months-11.29%
6 months+23.97%
Current year+30.71%
1 week 309.63
Extreme 309.63
326.98
1 month 309.63
Extreme 309.63
339.69
Current year 235.6
Extreme 235.605
382.54
1 year 184.02
Extreme 184.02
382.54
3 years 93.95
Extreme 93.95
382.54
5 years 38.86
Extreme 38.8563
382.54
10 years 8.03
Extreme 8.03
382.54
Manager TitleAgeSince
Chief Executive Officer 61 15/04/2016
Chief Operating Officer 61 15/04/2016
Investor Relations Contact - -
Director TitleAgeSince
Chairman 61 15/04/2016
Director/Board Member 61 15/04/2016
Director/Board Member 60 01/11/2016
Date Insider Type Main position Quantity % Market Cap. Importance
14/09/26 Free

Director

1,658 0.0056%
14/09/26 Free

Director

1,658 0.0056%
14/09/26 Free

Director

1,658 0.0056%
Change 5-day change 1-year change 3-year change Capi.($)
+0.21%+0.66%+74.14%+176.92% 9.51B
+6.64%+5.26%+69.07%+143.14% 1,148B
+1.24%+2.81%+47.45%+87.13% 652B
+1.09%+1.54%+28.62%+104.08% 505B
+0.80%+2.52%+54.38%+66.60% 384B
+4.89%+0.38%+70.71%+43.94% 348B
+2.56%+2.81%+34.52%+56.56% 294B
+2.37%+0.62%+3.98%+27.81% 264B
+1.42%+2.70%+57.43%+74.53% 244B
+1.24%+2.72%+36.26%+107.63% 197B
Average +2.22%+1.22%+47.66%+88.83% 404.67B
Weighted average by Cap. +3.16%+1.50%+50.24%+93.85%

Financials

2026 *2027 *
Net sales 497M 446M 412M 373M 697M 47.3B 706M 4.93B 1.96B 24.75B 1.86B 1.82B 78.58B 634M 569M 526M 476M 890M 60.4B 901M 6.29B 2.51B 31.61B 2.38B 2.33B 100B
Net income 225M 202M 187M 169M 316M 21.45B 320M 2.23B 890M 11.22B 845M 827M 35.63B 291M 261M 241M 218M 408M 27.68B 413M 2.88B 1.15B 14.48B 1.09B 1.07B 45.98B
Net Debt -610M -548M -506M -459M -857M -58.14B -867M -6.05B -2.41B -30.42B -2.29B -2.24B -96.59B -1.02B -915M -846M -766M -1.43B -97.12B -1.45B -10.11B -4.03B -50.82B -3.83B -3.75B -161B
Projected Income Statement - Annual - Krystal Biotech, Inc.
Logo Krystal Biotech, Inc.
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
Employees
295
Date Price Change Volume
29/10/26 $322.25 +0.26% 53,085
28/10/26 $321.42 +0.26% 199,841
27/10/26 $320.58 +2.21% 212,808
26/10/26 $313.66 +0.69% 223,645
23/10/26 $311.50 -2.70% 270,065
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Krystal Biotech, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
321.42USD
Average target price
395.44USD
Spread / Average Target
+23.03%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Krystal Biotech, Inc.
  1. Stock Market
  2. Stocks
  3. KRYS Stock